Sera Prognostics, Inc. Files 2023 Annual Report on Form 10-K

Ticker: SERA · Form: 10-K · Filed: Mar 20, 2024 · CIK: 1534969

Sentiment: neutral

Topics: 10-K, Sera Prognostics, Annual Report, Medical Laboratories, SEC Filing

TL;DR

<b>Sera Prognostics, Inc. has filed its 2023 10-K annual report detailing its financial performance and business operations.</b>

AI Summary

SERA PROGNOSTICS, INC. (SERA) filed a Annual Report (10-K) with the SEC on March 20, 2024. Sera Prognostics, Inc. filed its annual report on Form 10-K for the fiscal year ended December 31, 2023. The filing covers the period from January 1, 2023, to December 31, 2023. The company's principal business address is located at 2749 E. Parleys Way, Suite 200, Salt Lake City, UT 84109. Sera Prognostics, Inc. is classified under SIC code 8071 for Services-Medical Laboratories. The report was filed with the SEC on March 20, 2024.

Why It Matters

For investors and stakeholders tracking SERA PROGNOSTICS, INC., this filing contains several important signals. This 10-K filing provides a comprehensive overview of Sera Prognostics' financial health, operational activities, and strategic direction for the fiscal year 2023, which is crucial for investors to assess the company's performance and future prospects. As a medical laboratory services company, the detailed disclosures in this filing are important for understanding regulatory compliance, market positioning, and potential risks within the healthcare industry.

Risk Assessment

Risk Level: low — SERA PROGNOSTICS, INC. shows low risk based on this filing. The risk is assessed as low because the filing is a standard annual report (10-K) and does not contain immediate, significant negative financial or operational news. It serves as a routine disclosure of the company's status as of December 31, 2023.

Analyst Insight

Review the detailed financial statements and risk factors within the 10-K to understand Sera Prognostics' performance and potential challenges in the medical diagnostics sector.

Key Numbers

Key Players & Entities

FAQ

When did SERA PROGNOSTICS, INC. file this 10-K?

SERA PROGNOSTICS, INC. filed this Annual Report (10-K) with the SEC on March 20, 2024.

What is a 10-K filing?

A 10-K is a comprehensive annual financial report required by the SEC, covering audited financials, business operations, risk factors, and management discussion. This particular 10-K was filed by SERA PROGNOSTICS, INC. (SERA).

Where can I read the original 10-K filing from SERA PROGNOSTICS, INC.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by SERA PROGNOSTICS, INC..

What are the key takeaways from SERA PROGNOSTICS, INC.'s 10-K?

SERA PROGNOSTICS, INC. filed this 10-K on March 20, 2024. Key takeaways: Sera Prognostics, Inc. filed its annual report on Form 10-K for the fiscal year ended December 31, 2023.. The filing covers the period from January 1, 2023, to December 31, 2023.. The company's principal business address is located at 2749 E. Parleys Way, Suite 200, Salt Lake City, UT 84109..

Is SERA PROGNOSTICS, INC. a risky investment based on this filing?

Based on this 10-K, SERA PROGNOSTICS, INC. presents a relatively low-risk profile. The risk is assessed as low because the filing is a standard annual report (10-K) and does not contain immediate, significant negative financial or operational news. It serves as a routine disclosure of the company's status as of December 31, 2023.

What should investors do after reading SERA PROGNOSTICS, INC.'s 10-K?

Review the detailed financial statements and risk factors within the 10-K to understand Sera Prognostics' performance and potential challenges in the medical diagnostics sector. The overall sentiment from this filing is neutral.

Key Dates

Filing Stats: 4,299 words · 17 min read · ~14 pages · Grade level 17 · Accepted 2024-03-20 16:10:58

Key Financial Figures

Filing Documents

Business

Business 4 Item 1A.

Risk Factors

Risk Factors 40 Item 1B. Unresolved Staff Comments 79 I tem 1C. C ybersecurity 79 Item 2.

Properties

Properties 81 Item 3.

Legal Proceedings

Legal Proceedings 81 Item 4. Mine Safety Disclosures 81 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 82 Item 6. [ Reserved ] 82 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 82 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 90 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 92 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 116 Item 9A.

Controls and Procedures

Controls and Procedures 116 Item 9B. Other Information 117 Item 9C. Disclosure Regarding Foreign Jurisdiction that Prevent Inspections 118 PART III Item 10. Directors, Executive Officers and Corporate Governance 119 Item 11.

Executive Compensation

Executive Compensation 119 Item 12.

Security Ownership of Certain Beneficial Owner s and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owner s and Management and Related Stockholder Matters 119 Item 13. Certain Relationships and Related Transactions, and Director Independence 119 Item 14. Principal Accounting Fees and Services 119 PART IV Item 15. Exhibit and Financial Statement Schedules 120 Item 16. Form 10-K Summary 123

Signatures

Signatures 124 "Sera," "PreTRM," "The Pregnancy Company" and our logo are our trademarks. All other service marks, trademarks, and trade names appearing in this Annual Report on Form 10-K are the property of their respective owners. We do not intend our use or display of other companies' trade names, trademarks, or service marks to imply a relationship with, or endorsement or sponsorship of us by, these other companies. Solely for convenience, trademarks and tradenames referred to in this Annual Report on Form 10-K may appear without the or symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights, or that the applicable owner will not assert its rights, to these trademarks and tradenames. Unless the context otherwise requires, we use the terms "Sera," "Company," "we," "us" and "our" in this report to refer to Sera Prognostics, Inc. 2 Table of Contents SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This discussion contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. In some cases, you can identify forward-looking statements by words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "seek," "should," "target," "will," "would," or the negative of these words or other comparable terminology. These forward-looking statements include, but are not limited to, statements about: estimates of our addressable market, market growth, future revenue, key performance indicators, expenses, capital requirements, and our needs for additional financing; our expectations regarding the rate and degree of market acceptance of our PreTRM test; the impact of our PreTRM test on the field of bioinformatics and proteomics and the size

Business

Item 1. Business Overview We are a women's health company utilizing our proprietary proteomics and bioinformatics platform, and significant data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. Our vision is to deliver pivotal and actionable information to pregnant women, their physicians, and health care payers to significantly enhance a mother's pregnancy journey, improve maternal and neonatal health, and dramatically reduce health care costs. We believe that our method of combining the disciplines of proteomics and bioinformatics with rigorous clinical testing, data, and economic analysis enables us to provide physicians, patients, and consumers with personally insightful, clinically meaningful, and economically impactful information designed to improve the pregnancy experience and outcomes for mothers and babies. There are approximately 140 million births globally each year, and approximately 3.7 million births annually in the United States. Of these, it is estimated that as many as 30% are affected by various complications ( i.e. , a high-risk pregnancy), including: preterm birth, preeclampsia, fetal growth restriction, stillbirth, hypertension of pregnancy, gestational diabetes, and others. In many cases these complications have profound short- and long-term health consequences for the mother and baby. These health consequences of preterm birth alone are estimated to be approximately $25 billion annually in the United States. This underscores that existing methods to predict adverse pregnancy outcomes are insufficient for timely and effective proactive management for the vast majority of high-risk pregnancies. We believe that positive patient outcomes are the result of appropriate care, and the primary differentiator of patient care should be based on a determination of risk informed by a number of factors including our novel diagnost

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing